Potassium canrenoate
From Self-sufficiency
| File:Canrenoate potassium.png | |
| Systematic (IUPAC) name | |
|---|---|
|
potassium 3-[(8R,9S,10R,13S,14S,17R)- 17-hydroxy-10,13-dimethyl-3-oxo-2,8,9, 11,12,14,15,16-octahydro-1H-cyclopenta[a] phenanthren-17-yl]propanoate | |
| Clinical data | |
| Routes of administration | Intravenous |
| Pharmacokinetic data | |
| Metabolism | Hepatic |
| Excretion | Renal and fecal |
| Identifiers | |
| CAS Number | 2181-04-6 |
| ATC code | C03DA02 (WHO) |
| PubChem | CID 656614 |
| Chemical data | |
| Formula | C22H29KO4 |
| Molar mass | 369.516 g/mol[[Script error: No such module "String".]] |
Potassium canrenoate (INN) or canrenoate potassium (USAN), the potassium salt of canrenoic acid, is an aldosterone antagonist.
Like spironolactone, it is a prodrug, which is metabolized to canrenone in the body.
| 30px | This drug article relating to the cardiovascular system is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- 2Fix
- Aldosterone antagonists
- Steroids
- Potassium compounds
- Prodrugs
- Cardiovascular system drug stubs
